Better Context → Better Decisions

Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.

Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi Meets Primary Endpoint in Pivotal Trial for R/R CLL Access Free Blast

Posted in: Autologous, BCMA, CAR-T Jan 27 | 2023Carvykti’s CARTITUDE-4 Met its Primary Endpoint in r/r MM Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi 2L LBCL Absent from Third Consecutive Meeting; January’s CHMP Highlights Access Free Blast

Posted in: Autologous, BCMA, CAR-T, Topics Jan 25 | 2023Carvykti’s Revenue Remains Flat; CARTITUDE-4 Readout Expected in 2023; JNJ Q4 2022 Earnings Call Summary Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jan 23 | 2023Breyanzi Absent from January’s CHMP Agenda Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, TCR Jan 20 | 2023Thoughts on AstraZeneca's Cell Therapy Pipeline Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jan 13 | 2023JPM 2023 Analysis Day 4: Autolus and Caribou Biosciences Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T Jan 12 | 2023JPM 2023 Analysis Day 3: Century Tx, Atara Bio, and Precigen Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 11 | 2023Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSK Access Free Blast

Posted in: Autologous, BCMA, CAR-T, CD19 Jan 10 | 2023JPM 2023 Analysis Day 1: BMS, Novartis, JNJ, and Gilead Access Free Blast

Posted in: Autologous, CAR-T Jan 10 | 2023Thoughts on Gilead’s Acquisition of Tmunity Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 09 | 2023We're Back! Holiday Recap Ahead of JPM 2023 Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD123, CD19 Dec 19 | 2022You May Have Missed: ASH 2022 Analyses Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T Dec 16 | 2022Clinical Results from Autolus, Cellectis, and Precigen; ASH 2022 Analysis 7 Access Free Blast

Posted in: Autologous, BCMA, CAR-T, CD123 Dec 16 | 2022Updated Results from CART-ddBCMA in R/R MM; Could Gilead Take an Interest in the ARC-SparX Platform? Arcellx Meets Clinical Milestones; ASH 2022 Arcellx Investor Event Access Free Blast

Posted in: Autologous, CAR-T, CD19 Dec 16 | 2022Breyanzi 2L LBCL Absent from December’s CHMP Highlights Access Free Blast

Posted in: Autologous, CAR-T, CD19 Dec 15 | 2022Gilead, Novartis, and BMS Report Follow-up Data from Approved Lymphoma Therapies; ASH 2022 Analysis 6 Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19 Dec 14 | 2022Novartis, CRISPR Tx, and Miltenyi Report Clinical Updates from Their New Assets in Lymphomas; ASH 2022 Analysis 5 Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T Dec 14 | 2022BMS, Gracell, CARsgen, and Fate Tx Report Clinical Results from Next-Generation Assets in MM; ASH 2022 Analysis 4 Access Free Blast

Posted in: Autologous, CAR-T, CD19 Dec 12 | 2022Updated Results from Breyanzi and Yescarta in 2L LBCL; ASH 2022 Analysis 3 Access Free Blast

1 2 3 … 22 next »

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact UsLog In